header logo image header logo text
Downloads Login
Research
General Information
ZIRC
ZFIN ID: ZDB-FISH-150901-21362
Fish name: gl22Tg
Genotype: gl22Tg
Targeting Reagent: none
HUMAN DISEASE MODELED by gl22Tg
Human Disease Conditions Citations
cancer cancer xenotransplantation Hamilton et al., 2016
glioblastoma multiforme cancer xenotransplantation Hamilton et al., 2016
GENE EXPRESSION
Gene expression in gl22Tg
RNA expression
Expressed Gene Structure Conditions Figures
cdx1b control Fig. 3 with image from Okuda et al., 2015
chemical treatment: 2,4,6-trinitrobenzenesulfonic acid Fig. 3 with image from Okuda et al., 2015
csf1ra control Fig. 3 with image from Okuda et al., 2015
chemical treatment: 2,4,6-trinitrobenzenesulfonic acid Fig. 3 with image from Okuda et al., 2015
foxq1a standard conditions Fig. 2 with image from Earley et al., 2018
foxq1b standard conditions Fig. 2 with image from Earley et al., 2018
gbp4 control Fig. 1 from Tyrkalska et al., 2016
bacterial treatment by injection: Salmonella enterica subsp. enterica serovar Typhimurium Fig. 1 from Tyrkalska et al., 2016
htr2b standard conditions Fig. 3 with image from Yang et al., 2017
il1b control Fig. 1 from Tyrkalska et al., 2016
bacterial treatment by injection: Salmonella enterica subsp. enterica serovar Typhimurium Fig. 1 from Tyrkalska et al., 2016
mpx control Fig. 3 with image from Okuda et al., 2015
chemical treatment: 2,4,6-trinitrobenzenesulfonic acid Fig. 3 with image from Okuda et al., 2015
npsn control Fig. 1 with image from Di et al., 2017
caiap bacterial treatment by injection: Salmonella enterica subsp. enterica serovar Typhimurium Fig. 3 from Tyrkalska et al., 2017
trim9 control Fig. 2 from Tokarz et al., 2017
chemical treatment by environment: N-palmitoyl-S-[2,3-bis(palmitoyloxy)propyl]-Cys-Ser-Lys-Lys-Lys-Lys Fig. 2 from Tokarz et al., 2017
vegfaa control Fig. 3 with image from Okuda et al., 2015
chemical treatment: 2,4,6-trinitrobenzenesulfonic acid Fig. 3 with image from Okuda et al., 2015
vegfc control Fig. 3 with image from Okuda et al., 2015
chemical treatment: 2,4,6-trinitrobenzenesulfonic acid Fig. 3 with image from Okuda et al., 2015
vegfd control Fig. 3 with image from Okuda et al., 2015
chemical treatment: 2,4,6-trinitrobenzenesulfonic acid Fig. 3 with image from Okuda et al., 2015
PHENOTYPE
Phenotype in gl22Tg
Phenotype Conditions Figures
fatty acid transport process quality, abnormal bacterial treatment by injection: Salmonella enterica subsp. enterica serovar Typhimurium Fig. 8 from Hall et al., 2014
gall bladder morphology, abnormal chemical treatment: biliatresone Fig. 3 from Lorent et al., 2015
head macrophage increased amount, abnormal bacterial treatment by injection: Salmonella enterica subsp. enterica serovar Typhimurium Fig. 5Fig. 8 from Hall et al., 2014
head macrophage increased amount, ameliorated bacterial treatment by injection: Salmonella enterica subsp. enterica serovar Typhimurium, chemical treatment: PPARalpha agonist Fig. 8 from Hall et al., 2014
intestine macrophage amount, ameliorated chemical treatment: 2,4,6-trinitrobenzenesulfonic acid, chemical treatment: mesalamine Fig. 2 with image from Okuda et al., 2015
intestine macrophage increased amount, abnormal chemical treatment: 2,4,6-trinitrobenzenesulfonic acid Fig. 2 with image from Okuda et al., 2015
macrophage accumulation liver and biliary system, abnormal chemical treatment: biliatresone Fig. 3 from Lorent et al., 2015
macrophage EGFP expression decreased amount, abnormal chemical treatment by injection: monosodium urate Fig. 6 from Hall et al., 2018
macrophage il1b expression increased amount, abnormal bacterial treatment by injection: Salmonella enterica subsp. enterica serovar Typhimurium Fig. 1 from Tyrkalska et al., 2016
macrophage caiap expression increased amount, abnormal bacterial treatment by injection: Salmonella enterica subsp. enterica serovar Typhimurium Fig. 3 from Tyrkalska et al., 2017
macrophage EGFP expression increased amount, abnormal bacterial treatment by injection: Salmonella enterica subsp. enterica serovar Typhimurium Fig. 1 from Tyrkalska et al., 2016
macrophage trim9 expression increased amount, abnormal chemical treatment by environment: N-palmitoyl-S-[2,3-bis(palmitoyloxy)propyl]-Cys-Ser-Lys-Lys-Lys-Lys Fig. 2 from Tokarz et al., 2017
macrophage trim9 expression increased amount, abnormal chemical treatment by environment: poly(I:C) Fig. 2 from Tokarz et al., 2017
macrophage reactive oxygen species biosynthetic process increased occurrence, abnormal chemical treatment by injection: monosodium urate Fig. 6 from Hall et al., 2018
male organism macrophage htr2b expression increased amount, abnormal standard conditions Fig. 3 with image from Yang et al., 2017
neutrophil accumulation liver and biliary system, abnormal chemical treatment: biliatresone Fig. 3 from Lorent et al., 2015
reactive oxygen species biosynthetic process decreased occurrence, abnormal bacterial treatment by injection: Salmonella enterica subsp. enterica serovar Typhimurium, chemical treatment: PPARalpha agonist Fig. 6 with image from Hall et al., 2013
regenerating tissue macrophage decreased amount, abnormal transection: spinal cord, chemical treatment by environment: dexamethasone Fig. 1 from Tsarouchas et al., 2018
regenerating tissue macrophage increased amount, abnormal transection: spinal cord, chemical treatment by environment: lipopolysaccharide Fig. 1 from Tsarouchas et al., 2018
whole organism il1b expression increased amount, abnormal bacterial treatment by injection: Salmonella enterica subsp. enterica serovar Typhimurium Fig. 1 from Tyrkalska et al., 2016

CITATIONS  (43)